SCHEMBL3279768

SCHEMBL3279768

Cc1nnc2c(Cl)cccc2c1-c1cccc(O)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 10/20 0.43
HSD17B1 P14061 5/20 0.41
HSD17B2 P37059 4/20 0.41
NR1H3 Q13133 8/20 0.41
NR4A2 P43354 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
PIK3CD O00329 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278690 0.82 NR1H2 (0.53) NR1H2HSD17B1HSD17B2NR1H3MAPT
SCHEMBL35460 0.79 NR1H2 (0.61) NR1H2HSD17B1HSD17B2NR1H3
SCHEMBL5514193 0.78 NR1H2 (0.52) NR1H2NR1H3
SCHEMBL3278906 0.77 NR1H2 (0.72) NR1H2NR1H3
SCHEMBL3279843 0.75 NR4A2 (0.41) NR4A2CYP3A4CYP1A2TP53MAPT
SCHEMBL35186 0.74 NR1H2 (0.45) NR1H2HSD17B1HSD17B2NR1H3CYP3A4
SCHEMBL3279332 0.73 NR1H2 (0.60) NR1H2NR1H3
SCHEMBL3278882 0.73 NR1H2 (0.55) NR1H2NR1H3
SCHEMBL35232 0.72 NR1H2 (0.61) NR1H2HSD17B1HSD17B2NR1H3PIK3CD
SCHEMBL4013817 0.71 NR4A2 (0.54) HSD17B1HSD17B2NR4A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700595-B2 such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) WYETH LLC (US) 2010-04-20 US claimed
CN-101166730-A Cinnoline compounds and their use as liver X receptor modilators WYETH CORP (US) 2008-04-23 CN claimed
US-7700595-B2 such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) WYETH LLC (US) 2010-04-20 US disclosed
CN-101166730-A Cinnoline compounds and their use as liver X receptor modilators WYETH CORP (US) 2008-04-23 CN disclosed
EP-1853566-A1 CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS Wyeth (US) 2007-11-14 EP disclosed
US-20060252757-A1 Cinnoline compounds WYETH 2006-11-09 US disclosed
WO-2006094034-A1 CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS WYETH (US) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252757-A1 Cinnoline compounds NR1H3, NR1H2, CNR1 NR1H2 2/4885HSD17B1 53/4885HSD17B2 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.